ADVFN US – Market Content Editor
-

Onfolio Holdings Announces 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance
The reverse stock split is designed to restore compliance with Nasdaq’s minimum bid price requirement while reducing the company’s outstanding share count to approximately 850,000 shares. Key Investor Takeaways Why (NASDAQ:ONFO) Stock Is in Focus Onfolio Holdings (NASDAQ:ONFO) announced it will complete a 1-for-50 reverse stock split as part of its effort to regain compliance…
-

Commerce Reports Second-Quarter Profit as GMV Growth and AI Commerce Investments Support Outlook
The company delivered a second consecutive quarter of GAAP profitability while continuing to invest in AI-driven commerce capabilities and maintaining its full-year financial outlook. Key Investor Takeaways Why CMRC Stock Is in Focus Commerce (NASDAQ:CMRC) reported second-quarter revenue of $84.5 million, broadly unchanged from a year earlier, while Gross Merchandise Volume (GMV) increased 14% to…
-

Insmed Raises BRINSUPRI Revenue Guidance After Strong Q2 Growth and Expands Peak Sales Outlook
Strong commercial momentum for BRINSUPRI and continued growth from ARIKAYCE prompted Insmed to raise its 2026 outlook and increase peak revenue expectations for its lead programmes. Key Investor Takeaways Why INSM Stock Is in Focus Insmed (NASDAQ:INSM) reported total second-quarter 2026 revenue of $425.5 million, driven by continued commercial strength from BRINSUPRI, which generated $309.2…
-

Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand
Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes. Key Investor Takeaways Why (NASDAQ:IOVA) Stock Is in Focus Iovance Biotherapeutics (NASDAQ:IOVA) delivered record second-quarter revenue of approximately $99.3 million, a 66% increase from the prior-year quarter and a 39% improvement over…
-

Roche Expands Cyclospora Testing Portfolio to Support U.S. Public Health Response
The healthcare company has introduced two new research-use PCR tests as demand for cyclospora detection grows during an ongoing U.S. outbreak. Key Investor Takeaways Why RHHBY Stock Is in Focus Roche (USOTC:RHHBY) announced the launch of two new real-time PCR assays designed to detect Cyclospora cayetanensis, the parasite responsible for cyclosporiasis, as laboratories seek additional…
-

SurgePays Forms Redline Wireless Group to Expand Prepaid Wireless Distribution Across 20,000 Dealers
The joint venture significantly expands SurgePays’ nationwide distribution network and supports its long-term goal of exceeding one million wireless subscribers. Key Investor Takeaways Why SURG Stock Is in Focus SurgePays (NASDAQ:SURG) announced the creation of Redline Wireless Group, a joint venture designed to accelerate the distribution of its prepaid wireless services across one of the…
-

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
The transaction adds a clinical-stage pain therapy with FDA Orphan Drug Designation while providing funding expected to support development through Phase 2 data and into registrational planning. Key Investor Takeaways Why ENSC Stock Is in Focus Ensysce Biosciences (NASDAQ:ENSC) has completed its acquisition of private biotechnology company Cy Biopharma, bringing clinical-stage drug candidate CY200 into…
-

Papa John’s rules out near-term sale as turnaround takes centre stage
Papa John’s (NASDAQ:PZZA) has signalled that it is prioritising an internal turnaround over a sale of the business, bringing an 18-month strategic review to a close despite reported takeover interest from Qatari-backed Irth Capital Management. The announcement disappointed investors, with the pizza chain’s shares set to open around 12% lower on Thursday. Strategic review favours…
-

HubSpot shares plunge as cautious revenue outlook overshadows second-quarter beat
HubSpot Inc. (NYSE:HUBS) delivered second-quarter results ahead of Wall Street expectations, but its shares fell more than 20% after management issued full-year revenue guidance that came in below analysts’ forecasts. Despite reporting solid growth in revenue, earnings and customers, investors focused on the company’s more conservative sales outlook for the remainder of the year. Revenue…
-

Datadog shares tumble despite earnings beat and stronger full-year outlook
Datadog (NASDAQ:DDOG) shares plunged more than 21% in pre-market trading on Thursday, even after the cloud monitoring and cybersecurity specialist reported better-than-expected second-quarter results and lifted its full-year guidance. The sharp selloff appeared to reflect investor profit-taking following the stock’s recent record highs, rather than any deterioration in the company’s operating performance. Revenue and earnings…